Antibody therapies ineffective against Omicron variant BQ.1.1, says study

The coronavirus subvariant Omicron BQ.1.1 is resistant to all currently used therapeutic antibodies, researchers are warning. — dpa

Therapies for Covid-19 infections have greatly increased chances of patient survival since the start of the pandemic, and yet researchers believe one key form of therapy won't work against infections with a new subvariant.

Omicron BQ.1.1, which along with BQ.1 now makes up for the majority of infections in the United States and is rapidly spreading in other countries, is resistant to currently approved antibody therapies, the German Primate Center research institute says.